Alopecia Areata

Alopecia areata is an autoimmune disease in which T cells breach the hair follicle's normal immune privilege and attack it — producing anything from a single coin-sized smooth patch to loss of every scalp hair (alopecia totalis) or all body hair (alopecia universalis), plus the nail pitting that often accompanies. Lifetime risk is around 2%, onset is commonly before 40 and often in childhood, both sexes are affected, and the follicles are damaged but not destroyed — the biological basis for the disease's hallmark unpredictability: spontaneous regrowth is common in limited disease, relapse is always possible, and severe longstanding loss historically regrew rarely. It clusters with other autoimmunity (thyroid disease above all, plus vitiligo and atopy), and its psychological weight — identity, visibility, the daily explanation tax — is measured in depression and anxiety rates that treatment counselling must take as seriously as the follicles.

Until 2022, severe alopecia areata had no approved therapy anywhere — steroid injections for patches, off-label immunosuppressants, and wigs constituted the offer. The discovery that the follicular attack runs on interferon-gamma and IL-15 signalling through Janus kinases converted the disease into a druggable target, and three oral JAK inhibitors are now approved for severe disease: baricitinib (2022, adults), ritlecitinib (2023, from age 12), and deuruxolitinib (approved 2024, launched July 2025 after patent litigation; CYP2C9 genotyping required). The headline numbers, from programmes enrolling patients with at least half their scalp hair gone: roughly a third to 40% achieve 80%+ scalp coverage by six months to a year, indirect comparisons ranking deuruxolitinib's short-term efficacy highest — outcomes unimaginable a decade ago, in a population whose baseline expectation was zero.

The JAK story demands both celebration and fine print. Response is not universal — a majority of severe patients do not reach the headline regrowth thresholds, and longstanding total loss responds worst; the effect is suppressive, not curative — stopping typically brings relapse within months, making this indefinite therapy for a visible but non-lethal disease; the class carries boxed-warning baggage from other populations (thrombosis, cardiovascular events, malignancy in older rheumatoid patients on tofacitinib), with alopecia-trial safety so far reassuring — mostly acne, headache, infections — but long-term surveillance genuinely young; and cost plus prior-authorisation friction rations access in most systems. Adolescent data are strengthening (ritlecitinib approved from 12; baricitinib's paediatric programme reported near-complete regrowth in severe adolescent disease in late 2025), with younger-child use still investigational.

Because JAK therapy is reserved for severe disease, most alopecia areata is still managed conventionally — and reasonably: limited patches receive intralesional corticosteroid injections (the workhorse, with regrowth in most injected patches), potent topical steroids especially in children, and minoxidil as an adjunct accelerant; extensive disease in specialist hands may try topical immunotherapy (DPCP sensitisation), which regrows hair in a substantial minority through deliberate low-grade contact allergy; and watchful waiting is legitimate in new limited disease, where spontaneous regrowth rates are high. Oral minoxidil increasingly rides alongside JAK inhibitors as a regrowth accelerant. What does not work deserves equal clarity: the supplement-and-oil marketplace targeting alopecia patients sells to desperation, and nothing in it has trial support beyond correcting genuine deficiencies.

Alopecia areata's burden concentrates in visibility and unpredictability, and management that ignores this fails patients even when follicles respond. The practical layer: modern wigs and hair systems (increasingly prescription-subsidised), brow micropigmentation and lash options, scalp protection from sun; the psychological layer: measured elevations in anxiety and depression warrant proactive asking, children face school and bullying dimensions with real support-group evidence, and identity responses legitimately diverge — some patients pursue every treatment, others (including a visible public cohort) decline treatment entirely and normalise baldness, and both are valid endpoints; the community layer: patient organisations supply navigation, camps for children, and the advocacy that pushed the disease from cosmetic dismissal to approved therapy. Clinicians' single highest-yield habit: treating the disease as the serious autoimmune condition it is, in vocabulary and in referral reflexes.

New patches: see a dermatologist within weeks, not months — injections work best early, spontaneous regrowth is common, and thyroid screening is routine. Severe or rapidly progressive disease: ask specifically about JAK inhibitors — eligibility typically starts around half-scalp loss; expect a frank conversation about response odds (a third to 40% reach near-full regrowth), indefinite duration, relapse on stopping, monitoring, and cost navigation. Children and adolescents: ritlecitinib from 12, strengthening adolescent data, and paediatric dermatology for the rest. Everyone: skip the supplement aisle, screen the mood honestly, use the patient organisations — and know that both fighting for every hair and declining the fight entirely are respectable ways to own this disease.